Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
General Internal Medicine
Is there a scenario where you would consider multiple NSCLC lesions in the same lobe as multifocal synchronous malignancies rather than intrapulmonary metastases, (ie, mpT1 rather than T3?
Related Questions
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
Would you consider the combination of amivantamab and lazertinib in a patient with NSCLC harboring an EGFR exon 19 deletion that transformed to small cell carcinoma on osimertinib, if resistance profiling still detects the EGFR mutation?
How do you approach duration of immunotherapy in patients with metastatic NSCLC?
How would you approach the management of a patient with Stage IV NSCLC harboring both a classical and non-classical compound EGFR mutations?
How do you approach Tarlatamab use in an elderly patient with relapsed ES SCLC?
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
What is your workup for amyloidosis diagnosed via biopsy during carpal tunnel release surgery?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
Should a patient with resected stage IIIA lung adenocarcinoma harboring an STK11 mutation receive adjuvant immune checkpoint inhibitor therapy following the completion of adjuvant chemotherapy?
